Another Connecticut Fundraiser for Teacher with Hodgkin's

And I thought community dinners were a Minnesota thing ;-)



Friends are rallying around Ericka Banhan, a longtime Bethlehem, CT resident employed as a part-time Middle School secretary. Ericka is the wife of self-employed painter Ozzie Banhan and the mother of Alexis, 14, entering her sophomore year in High School, and Brooke, 9, who just completed third grade.



Ericka was diagnosed in April with Stage IV Hodgkin's lymphoma. She has no health insurance.



Friends are coordinating "An Evening for Ericka", a dinner dance and silent auction set for 7 to 11 p.m. Friday, July 15. Gathered recently to finalize details of the event, woman spoke fondly of Ericka. Students love her, they said; despite her illness, she is seldom without a smile.



"Ericka is so fun to be around," said Lisa. "She has so much heart and she's devoted to her kids. She always puts her girls first." "If the situation were reversed, she'd be there for all of us," said Nancy. Gayle Peterson can vouch for that. Nearly 10 years ago, she, too, was diagnosed with Hodgkin's and Ericka was among those offering support.



"I'd be sick from my chemo treatments and Ericka would be there, bringing meals to my door," she said. "She was so helpful. Ericka's a wonderful person."
More in the Voices newspaper.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap